Immunochemotherapy combined with antiangiogenic

Phase 2Small molecule

IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Immunochemotherapy combined with antiangiogenic is one of 35 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Resectable NSCLCNot yet recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Resectable NSCLCPhase 2

Not yet recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Immunochemotherapy combined with antiangiogenic

IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 2

1 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Valemetostat

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Resectable NSCLC

NCT06475755

Q4 2028

Recruiting

Hepatocellular Carcinoma

NCT06777628

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna··NCT06777628·100 enrolled

Resectable NSCLC1 trial

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT06475755·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Immunochemotherapy combined with antiangiogenic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunochemotherapy combined with antiangiogenic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunochemotherapy combined with antiangiogenic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IRCCS Azienda Ospedaliero-Universitaria di Bologna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Immunochemotherapy combined with antiangiogenic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Resectable NSCLC1 trial

References

Drug Info

Quick Facts

Related News